Colorectal CancerFDA Approvals, News & UpdatesNewsworthy

Opdivo Approved for dMMR and MSI-H Metastatic Colorectal Cancer

December 2017 Vol 3 No 6

On July 31, 2017, the FDA approved a new use for Opdivo (nivolumab; from Bristol-Myers Squibb) for adults with mismatch repair–deficient (dMMR) and microsatellite instability–high (MSI-H) metastatic colorectal cancer that progressed after treatment with a chemotherapy regimen.

The approval of this new indication was based on a clinical trial showing that 28% of adult patients responded to treatment with Opdivo, including 1 complete response (no sign of disease) and 14 partial responses. In 67% of patients, the responses lasted 6 months or longer. Among the 74 patients in the overall population, there was an objective response rate of 32%.

Opdivo was previously approved by the FDA for many types of cancer, including melanoma, lung cancer, kidney cancer, head and neck cancer, liver cancer, lymphoma, and bladder cancer.

Recommended For You
FDA Approvals, News & UpdatesNewsworthyWeb Exclusives
FDA and CDC Investigate Outbreak of Vaping-Related Illness
In the past week, the US Food and Drug Administration (FDA) has released 2 public announcements related to the use of vaping products.
Colorectal CancerPatient Stories
Recovering from Survivor Guilt After Surviving Hurricane Katrina and Colorectal Cancer
By Jamie D. Aten, PhD
As a psychologist dedicated to helping people cope with disasters, Jamie D. Aten knew the damage “survivor’s guilt” can do. As a stage IV colon cancer survivor, he says, “I wasn’t prepared for it to hit me personally.”
FDA Approvals, News & UpdatesLymphoma
Polivy a New Targeted Immunotherapy Approved for Patients with B-Cell Lymphoma
In June 2019, the FDA approved a new type of immunotherapy called Polivy, for use in combination with other drugs, in patients with previously treated diffuse large B-cell lymphoma (DLBCL), offering new options for patients whose cancer has returned.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.